Why is Pfizer falling/rising?

As of 22-Jul, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,284.60, which reflects a decrease of 43.9 points or 0.82%. Today's price summary indicates that the stock's performance is in line with its sector, but it has seen a decrease in investor participation, with a delivery volume drop of 6.14% compared to the 5-day average. The stock's returns over the past week and month are negative at -2.84% and -5.44%, respectively, while it has shown a modest year-to-date gain of 0.58%. Despite these short-term declines, the company boasts strong financial metrics, including a high return on equity of 19.67% and a low debt-to-equity ratio, which suggests solid management efficiency and financial health.
In the broader market context, Pfizer's recent performance contrasts with the Sensex, which has only declined by 0.47% over the past week and 0.27% over the past month. This indicates that while the stock is underperforming relative to the benchmark, it has outperformed over the longer term, with a 1-year return of 5.76% compared to the Sensex's 2.09%. The stock's liquidity remains adequate, allowing for trades of Rs 0.24 crore, and it offers a high dividend yield of 3.75%, which may attract long-term investors despite the recent price drop. Overall, while Pfizer's stock is currently facing downward pressure, its underlying financial strength and dividend yield may provide support for its valuation in the long run.